Antimetabolites: Fake Building Blocks That Jam DNA Synthesis
A dividing cell must copy its DNA, and to do that it needs a steady supply of nucleotide building blocks. Antimetabolites are counterfeit blocks — molecules so similar to the real thing that the cell either uses them and chokes, or the enzymes that make the real ones get blocked. The trick is that this hits fast-copying cells hardest — including the cancer. Master how these fakes work and you understand the S-phase, the folinic-acid rescue that saves the patient, and why one missing enzyme can turn a routine dose into a lethal one.
A young woman with acute leukaemia lies in the infusion suite as a high dose of methotrexate drips into her vein — a dose far higher than anything the body normally tolerates. Then something strange happens. Hours later the nurse returns and deliberately gives her a "vitamin." It is folinic acid (leucovorin), and it is not a mistake — it is the whole plan. The poison went in first; the antidote is timed to arrive only once the cancer cells are already committed to dying, while the healthy cells still have time to be rescued. Give the rescue too early and you spare the tumour; too late and you lose the patient. The art of this treatment is entirely in the clock.
The core idea: counterfeit building blocks
To copy DNA, a cell needs nucleotides and the folate cofactor that helps build them. Antimetabolites exploit that dependency. Each drug is a structural mimic of a normal metabolite — a purine, a pyrimidine, or folic acid itself. Once inside the cell it does one of two things: it gets incorporated into the growing DNA/RNA strand as a defective brick that jams the machine, or it competitively inhibits the enzyme that manufactures the real nucleotide, starving the cell of raw material. Either way, DNA synthesis fails. Because this failure only matters when a cell is actively copying its DNA, antimetabolites are cell-cycle-specific: they act mainly in the S phase (the DNA-synthesis phase). That single fact explains both their targets and their toxicities.
S-phase specificity is a double-edged sword. It means antimetabolites spare resting cells but hammer any tissue that divides constantly — bone marrow, gut lining, hair follicles. That is exactly why myelosuppression and mucositis are the signature toxicities of this whole class, not a quirk of one drug.
The folate antagonists: methotrexate and pemetrexed
Methotrexate is the archetype. It is a near-perfect mimic of folic acid, and it binds and inhibits dihydrofolate reductase (DHFR) — the enzyme that regenerates the active, reduced folate (tetrahydrofolate) the cell needs. With DHFR blocked, the cell cannot make thymidylate (the T of DNA) or the purines, so DNA synthesis grinds to a halt. Its uses split into two worlds by dose: at high oncological doses it treats leukaemias, lymphomas and others; at low weekly doses it is a cornerstone immunosuppressant in rheumatoid arthritis, psoriasis and other autoimmune disease — same enzyme, very different intent.
Folinic acid is a ready-made reduced folate that bypasses the DHFR block entirely — it does not need the blocked enzyme to become active. Given after high-dose methotrexate, it refills the folate pool of normal cells and lets them recover ("leucovorin rescue"), while tumour cells that took up too much methotrexate cannot be saved. Methotrexate is also cleared renally, and it lingers dangerously in "third spaces" like pleural effusions or ascites, slowly leaking back out — so before high-dose therapy we hydrate, alkalinize the urine, and monitor levels, draining large effusions first.
Pemetrexed is a newer, multi-targeted antifolate: it inhibits thymidylate synthase and other folate-dependent enzymes as well as DHFR. It is a mainstay in non-squamous non-small-cell lung cancer and in mesothelioma. Crucially, it is co-prescribed with folic acid and vitamin B12 supplementation — not to rescue after the fact, but to blunt its marrow and mucosal toxicity from the start, which sharply improves its safety.
- Methotrexate inhibits DHFR → no reduced folate → no thymidine/purine synthesis.
- High-dose methotrexate is rescued with folinic acid (leucovorin), which bypasses DHFR.
- Methotrexate is renally cleared and accumulates in effusions/ascites — hydrate and alkalinize.
- Low-dose weekly methotrexate treats autoimmune disease (RA, psoriasis).
- Pemetrexed is given WITH folic acid + B12 to reduce toxicity upfront.
The pyrimidine analogues: 5-FU, capecitabine, cytarabine, gemcitabine
5-fluorouracil (5-FU) is a fake uracil. Once activated inside the cell, its main weapon is inhibition of thymidylate synthase — the enzyme that makes thymidylate — so, like methotrexate but by a different door, it starves DNA of its T. It is a backbone of colorectal, breast and gastrointestinal cancer. Its toxicities follow the fast-dividing tissues: mucositis, diarrhoea, myelosuppression and the distinctive hand-foot syndrome (painful, red, peeling palms and soles). Capecitabine is an oral prodrug that is converted to 5-FU in the body — preferentially in tumour tissue — giving the convenience of a pill with a similar toxicity profile, colorectal and breast cancer being major uses.
5-FU is broken down by the enzyme dihydropyrimidine dehydrogenase (DPD). Patients with inherited DPD deficiency clear 5-FU (and capecitabine) far too slowly, so a standard dose accumulates to catastrophic, sometimes fatal, toxicity — severe mucositis, marrow failure and neurotoxicity. This is why DPD testing before fluoropyrimidine therapy is increasingly standard: one enzyme decides whether a routine dose is safe or lethal.
Cytarabine (ara-C) is a fake cytidine that gets incorporated into DNA and stalls the polymerase; it is the backbone of induction therapy for acute myeloid leukaemia (AML), classically paired with an anthracycline. Gemcitabine, another cytidine analogue, both incorporates into DNA and inhibits nucleotide synthesis; it is widely used in pancreatic and non-small-cell lung cancer, among others. Notice the pattern: each pyrimidine analogue is a slightly different fake, but all of them sabotage DNA synthesis in the S phase.
- 5-FU inhibits thymidylate synthase; toxicities: mucositis, diarrhoea, hand-foot syndrome.
- Capecitabine is an oral prodrug converted to 5-FU, favouring tumour tissue.
- DPD deficiency causes severe, potentially fatal fluoropyrimidine toxicity — test first.
- Cytarabine (ara-C) is the backbone of AML induction.
- Gemcitabine is a cytidine analogue used in pancreatic and lung cancer.
The purine analogues: thiopurines and beyond
The purine mimics complete the family. 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are fake purines that, after activation, block purine synthesis and get incorporated into DNA. 6-MP is a mainstay of maintenance therapy in acute lymphoblastic leukaemia (ALL). Fludarabine and cladribine are purine analogues too; cladribine is famously effective — often with a single short course — in hairy cell leukaemia, while fludarabine is used in chronic lymphocytic leukaemia and lymphomas. The thiopurines carry their own two classic drug-interaction and pharmacogenetic traps that examiners love.
First, TPMT: 6-MP is inactivated partly by thiopurine methyltransferase (TPMT). Patients with inherited TPMT deficiency accumulate toxic metabolites and suffer severe, sometimes life-threatening myelosuppression on standard doses — so TPMT status guides dosing. Second, allopurinol: 6-MP is also broken down by xanthine oxidase, the very enzyme allopurinol blocks. Co-prescribe allopurinol (e.g. for gout or tumour lysis) without reducing the 6-MP dose and levels soar into dangerous toxicity. The classic teaching is to cut the 6-MP dose to roughly a quarter — or avoid the combination.
- 6-MP and 6-TG block purine synthesis; 6-MP is core to ALL maintenance.
- TPMT deficiency → toxic thiopurine metabolites → severe myelosuppression.
- Allopurinol blocks xanthine oxidase and raises 6-MP levels — reduce the dose.
- Cladribine is highly effective in hairy cell leukaemia; fludarabine in CLL/lymphoma.
Two threads run through the whole class and reach into other chapters. Methotrexate's low-dose role in autoimmune disease is really a story of controlled folate antagonism — the same logic you meet again in the Inflammation section and, from the nutritional side, in the B12 & folate chapter of Haematology (which is why folate supplementation matters). And the pharmacogenetic traps — DPD before a fluoropyrimidine, TPMT before a thiopurine — are the clinical face of the individual-variation ideas from Pharmacodynamics: the same dose, a very different patient. Cytarabine's leading role in AML connects to the blood-cancer chapters, and capecitabine/5-FU in colorectal disease to the Colorectal chapter.
- Giving high-dose methotrexate without folinic-acid rescue, hydration and urine alkalinization — a recipe for fatal toxicity.
- Co-prescribing NSAIDs or trimethoprim with methotrexate: both raise methotrexate levels/toxicity (reduced renal clearance and added antifolate effect).
- Starting a fluoropyrimidine without considering DPD deficiency, or a thiopurine without TPMT status — ignoring pharmacogenetics.
- Adding allopurinol to 6-MP at the usual dose, forgetting xanthine oxidase inhibition sends 6-MP levels soaring.
A patient receives high-dose methotrexate. Which agent is given afterward to rescue normal cells, and why does it work?
- Antimetabolites are fake purines, pyrimidines or folate that jam DNA synthesis in the S phase.
- Methotrexate inhibits DHFR; high doses are rescued with folinic acid, not folic acid.
- 5-FU/capecitabine hit thymidylate synthase; DPD deficiency makes them dangerous.
- Thiopurines (6-MP/6-TG): watch TPMT deficiency and the allopurinol interaction.
- Myelosuppression and mucositis are the class-wide toxicities — timing and pharmacogenetics decide safety.
- Katzung BG. Basic & Clinical Pharmacology — Cancer Chemotherapy: antimetabolites (folate, pyrimidine & purine analogues).
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Antimetabolites & cytotoxic agents.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Anticancer drugs: antimetabolites.
- Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy — Methotrexate, fluoropyrimidines & thiopurines.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Anticancer drugs: antimetabolites & pharmacogenetics (TPMT, DPD).
